Sarepta Therapeutics Inc. (NASDAQ:SRPT) shares were down 7.1% during mid-day trading on Wednesday . The company traded as low as $23.51 and last traded at $24.66, with a volume of 2,308,942 shares traded. The stock had previously closed at $26.54.

A number of research analysts recently issued reports on SRPT shares. Robert W. Baird reiterated a “buy” rating and set a $23.00 price objective (down from $47.00) on shares of Sarepta Therapeutics in a report on Saturday, April 23rd. Needham & Company LLC restated a “buy” rating and issued a $20.00 price target (down from $53.00) on shares of Sarepta Therapeutics in a research note on Sunday, April 24th. Oppenheimer Holdings Inc. restated a “buy” rating and issued a $60.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, April 21st. Vetr downgraded Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating and set a $17.92 price target for the company. in a research note on Monday, April 25th. Finally, WBB Securities restated a “buy” rating and issued a $40.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, April 26th. Five investment analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. Sarepta Therapeutics has a consensus rating of “Hold” and an average price target of $25.28.

The firm’s 50-day moving average is $22.08 and its 200 day moving average is $18.08. The company’s market capitalization is $1.10 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the company earned ($0.87) earnings per share. Equities analysts anticipate that Sarepta Therapeutics Inc. will post ($5.13) earnings per share for the current fiscal year.

Several institutional investors have added to or reduced their stakes in SRPT. Nationwide Fund Advisors raised its position in Sarepta Therapeutics by 9.2% in the fourth quarter. Nationwide Fund Advisors now owns 29,223 shares of the company’s stock valued at $1,127,000 after buying an additional 2,471 shares in the last quarter. Swiss National Bank raised its position in shares of Sarepta Therapeutics by 5.8% in the fourth quarter. Swiss National Bank now owns 61,700 shares of the company’s stock valued at $2,380,000 after buying an additional 3,400 shares during the period. Rhumbline Advisers raised its position in shares of Sarepta Therapeutics by 16.1% in the fourth quarter. Rhumbline Advisers now owns 47,728 shares of the company’s stock valued at $1,841,000 after buying an additional 6,615 shares during the period. New York State Common Retirement Fund raised its position in shares of Sarepta Therapeutics by 13.5% in the fourth quarter. New York State Common Retirement Fund now owns 44,700 shares of the company’s stock valued at $1,725,000 after buying an additional 5,300 shares during the period. Finally, Mutual of America Capital Management LLC raised its position in shares of Sarepta Therapeutics by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 60,108 shares of the company’s stock valued at $2,319,000 after buying an additional 358 shares during the period.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.